SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001193125-18-096031
Filing Date
2018-03-26
Accepted
2018-03-26 16:44:46
Documents
50
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A d553905d10qa.htm 10-Q/A 319480
2 EX-31.1 d553905dex311.htm EX-31.1 5998
3 EX-32.1 d553905dex321.htm EX-32.1 3157
  Complete submission text file 0001193125-18-096031.txt   2440245

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT rxii-20170930.xml EX-101.INS 421113
5 XBRL TAXONOMY EXTENSION SCHEMA rxii-20170930.xsd EX-101.SCH 28046
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rxii-20170930_cal.xml EX-101.CAL 42375
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rxii-20170930_def.xml EX-101.DEF 126355
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rxii-20170930_lab.xml EX-101.LAB 246377
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rxii-20170930_pre.xml EX-101.PRE 190292
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-36304 | Film No.: 18713239
SIC: 2834 Pharmaceutical Preparations